Natera, Inc. with ticker code (NTRA) have now 18 market analysts covering the stock. The analyst consensus now points to a rating of ‘strong_buy’. The range between the high target price and low target price is between $209.00 and $37.00 suggesting an average analyst share price target price of $166.51. (at the time of writing). Given that the stocks previous close was at $167.12 this is indicating there is a potential downside of -.4%. Also worth taking note is the 50 day moving average now sits at $141.74 while the 200 day moving average is $114.65. The total market capitalization for the company now stands at 22.06B. Currently the stock stands at: $166.45 USD
The potential market cap would be $21,982,307,943 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of $12.59 and a -9.96% return on assets.
Natera, Inc. is a diagnostics company that is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company’s product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening (HCS), Spectrum Preimplantation Genetics, Anora Miscarriage Test (Anora) and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
